• Gilead forecast Q1 2026 acquired IPR&D expense of about $107 million.
• Charge expected to reduce GAAP diluted EPS by about $0.07.
• Non-GAAP diluted EPS impact also projected at about $0.07.
• Estimate includes an $80 million upfront payment tied to Genhouse collaboration announced Feb. 13, 2026.
• Full-year 2026 IPR&D guidance of $300 million issued Feb. 10, 2026 excluded Genhouse payment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on April 09, 2026, and is solely responsible for the information contained therein.